Cytotoxic activity and physicochemical properties of gendarusin A-E compounds on estrogen alfa receptors (2JF9) by Indrawijaya, Yen Yen Ari et al.
56 
J. Islamic Pharm. 2019. 4(1): 56-64 
 
J. Islamic Pharm., an open access journal 
ISSN: 2527-6123 
CYTOTOXIC ACTIVITY AND PHYSICOCHEMICAL PROPERTIES OF 
GENDARUSIN A-E COMPOUNDS ON ESTROGEN ALFA RECEPTORS (2JF9) 
Yen Yen Ari Indrawijaya1*, Nur Ika Octavia1, Roihatul Mutiah1, Weka Sidha Bhagawan1, 
Burhan Ma’arif1 
 
1Department of Pharmacy, Faculty of Medicine and Health Sciences, UIN Maulana Malik Ibrahim Malang, East 
Java, Indonesia 
 
*Corresponding author: yenyen.pharmacist@gmail.com 
 
ABSTRACT 
Estrogen Alfa (ERα) is a receptor used as the main marker to identify the presence of tumors in 
the breast.compounds Gendarusin A-E have anticancer activity by inhibiting the poliferation of cancer 
cells and inducing apoptosis. The purpose of this research are to predict the cytotoxic activity, 
physicochemical properties, and toxicity of the gendarusin A-E compound. The predictions of 
physicochemical properties were tested in compliance with the Five Lipinski Rules and the results of the 
ADME process (absorption, distribution, metabolism, and excretion) using the application pkCSM Online 
tool. Prediction of cytotoxic activity using Molegro Virtual Docker (MVD) by validating receptors and 
molecular docking. Cancer receptor protein used in Estrogen Alfa with PDB code 2JF9. Toxicity 
prediction using the Protox II Online tool. The results of this study indicate that the Gendarusin A-E 
compound didn’t completed the Five Lipinski Rules. Gendarusin A-E compounds had activity against 
receptors Estrogen Alpha which is shown by the results of RMSD <2 and Gendarusin A compounds had 
the smallest Rerank Score of -70.9817 compared to other compounds. Gendarusin B compound had the 
highest LD50  1212 mg / kg and classified in grade 4. 
Keywords: Gendarusin A-E, Breast Cancer, Alfa Estrogen (ER α), Cytotoxic Activity, Molecular 
Docking 
INTRODUCTION 
Breast cancer is one type of tumor that grows in breast tissue such as: mammary glands, 
milk ducts, fat tissue, and connective tissue in the breast [1]. Cancer prevalence is based on Basic 
Health Research [2] of 1.4 per 1000 occupations and is among the most common causes of death 
under cardiovascular disease. Chemotherapy and radiotherapy are the most effective treatment 
for cancer metastasis and non-metastasis [3]). The most commonly used breast cancer drug is 
Tamoxifen but it has side effects that cause cervical cancer in long-term use. Therefore, it is 
necessary to develop new drugs as breast anticancer using natural ingredients. The initial way to 
find out the activities of a plant quickly and does not require expensive costs is to use the method 
In Silico Molecular (Docking). This method is used to predict whether the chemical content in a 
plant has anticancer activity by comparing with compounds whose effects are known as 
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anticancer [4]. Plants that have the potential to be anticancer are gandarusa (Justicia 
gendarussa). Gandarusa has activity as cervical anticancer on Hela cells and colon anticancer on 
HT-29 cells [5]. This plant contains a flavonoid compound which has been isolated, namely 
gendarusin A-E. This compound has anticancer activity which inhibits the proliferation of cancer 
cells by inhibiting the cell cycle and inducing apoptosis [6]. Breast cancer has receptors, one type 
of receptor is Estrogen Alfa (ER α) which is antagonistic (inhibits the growth of cancer cells). 
This receptor is the main marker to identify the presence of tumors in breast tissue [7]. In silico 
test is done by connecting the flavonoid compound structure (Gendarusin A-E) against the breast 
cancer receptors (Estrogen Alfa). Based on these descriptions, this research needs to be done to 
develop new drugs as breast anticancer by knowing the physicochemical properties using apps 
pkCSM Online Tools and Basic of Five Lipinski  Rules, cytotoxic activity with the interaction 
between multiple ligands to the receptor, and toxicity using Protox II Online Tool to get LD50 
value. 
 
MATERIAL AND METHOD 
Materials 
Chem Bio Draw Ultra12.0, Bio Chem 3D Ultra 12.0, Molegro Virtual Docker 6.0 (Molegro 
ApS), pkCSM Online Tool, and Protox II Online Tool. The structure of the gedarusin A-E 
compound and the three-dimensional structure of the receptor Estrogen Alpha (ER α). 
Study Design  
ER α PDB code: 2JF9 downloaded from the Protein Data Bank (https://www.rcsb.org/).The 
SMILES code is downloaded from the SMILES Translator Program 
(https://cactus.nci.nih.gov/translate/). 
Prediction of Physicochemical Properties and Toxicity 
Prediction of Physicochemical Properties and Toxicity using SMILES code and pkCSM Online 
Tool, then predicted based on the Five Lipinski law. As for toxicity, use the Protox II Online 
Tool and classify it into the toxicity class. 
Docking and Amino Acid Analysis 
Docking and amino acid analysis can be done using the Molegro Virtual Docker program, and all 
stages use 3D image forms. There are several steps to the docking process, namely: (1). 
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Download receptors from the Protein Data Bank website. The receptors that are downloaded 
must contain ligands. (2). Adding H atoms to the receptor (because the receptor downloaded is 
removed) and fixing the receptor protein downloaded, if there are errors / deficiencies of amino 
acids present. This stage is usually done automatically by a computer program. (3). Detection of 
position at the receptor, where the drug will be bound (interact). These arecavitiesin the receptor 
structure. (4). Put the 3D structure of the compound into the selected hole. There are several 
ways to put the structure of a compound in a hole, in the Molegro Virtual Docker program it is 
done by "allign" which is to attach three atoms of a compound to the same three atoms on a 
ligand in the receptor. The selected atoms are generally the atoms in the pharmacophore group. 
(5). Look at the picture (view) the position of compounds in receptor holes (cavities). There are 
several pictures to look at the environment of compounds, including: hydrophobic picture, to see 
the hydrophobic environment of a compound, an electronic picture, to see the electronic 
environment of a compound, and a picture of the H bonding of compounds and receptors. Amino 
acids involved in the process of drug-receptor interactions and pharmacophore groups can be 
seen from the picture of the H bonds of compounds and receptors. (6). Docking compounds at 
the receptor, which is done automatically with the Molegro Virtual Docker program. Things that 
need to be considered in this process are the selection of the docking compound and the cavity 
where the drug will interact. The parameters measured in the docking process are the energy 
values involved, in the form of MolDock Score, Rerank Score, and H bond, and RMSD (Root 
Mean Square Deviation). To measure the strength of drug-receptor binding, a parameter often 
used is the Rerank Score [8]. 
 
RESULT AND DISCUSSION  
Prediction of Physicochemical Properties and Toxicity 
Prediction results of physicochemical properties using pkCSM Online Tool compound 
AE gendarusin none meet the criteria of Five Lipinski Law BM <500, Log P <5, Torsion 0-15, H 
Bond Acceptor <10, H Bond Donor <5, and PSA <140. Based on these results it can be seen that 
the compound Gendarusin A-E does not meet Lipinski's Law which means it has low absorption 
and permeability [9]. Table 1 shows the predicted results of physicochemical properties and 
toxicity. 
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Toxicity prediction results show that Gendarusin A-E compounds are classified as class 4 
with susceptible LDvalues50 566-1213 which means less toxic, the higher the LDvalue50, the 
lower the toxicity. If a compound is classified as class 4 it means that it shows relatively low 
toxicity [10]. Based on table 1, compounds Gendarusin A, C, D, E cause toxicity to bacteria 
while Gendarusin B does not. Gendarusin AE does not cause toxicity to the liver and sensitivity 
to the skin. 
Validation of Estrogen Alfa Receptor 
Validation is performed using ValrogenMolegro Virtual Docker 6.0 by docking back 
native ligands on receptor holes resulting from the receptor validation process, namely the 
RMSD (Root Mean Square Devitiation) value with an ideal value <2Å [11]. The results of 
receptor validation are shown in table 2 and the best positions of ligands and receptors are shown 
in Figure 1. The results obtained fromreceptors Estrogen Alfa Chain A have an ideal RMSD 
value of 0.81054. 
In Figure 2 shows the hydrogen bonds and steric bonds that occur between amino acids 
and ligands. Gendarusin A and D compounds have amino acid residues Asp 351, Glu 380, and 
Trp 383, gendarusin B Ala 340, Asp 351, Leu 346, Thr 347, and Leu 525, gendarusin C has only 
one residue, Glu 380, Gendarusin E Leu 525, Asp 351, and Glu 380. While tamoxifen as a 
comparison does not have active residues, but has an electrostatic interaction Asp 351. 
The results of the process docking between the Gendarusin A-E compound and 
tamoxifen with thereceptor Estrogen Alpha (ER α) with PDB code 2JF9 have a Rerank Scores of 
-70.9817 (gendarusin A), -68.9485 (gendarusin B), -67.1363 (gendarusin C), -67.66663 
(gendarusin D), -69.6190 (gendarusin E), and -101,287 (tamoxifen) shown in Table 3. 
Discussion 
 The aim of this study is to predict the physicochemical properties, cytotoxic activity, and 
toxicity of the gendarusin AE compound againstreceptors Estrogen Alfa (ER α). Aandarusin AE 
compounds do not meet the Five Lipinski legal requirements in the process of predicting 
physicochemical properties. This means that the five compounds have low absorption and 
permeability. The provisions of the Five Lipinsk law are molecular weights <500, Log P <5, 
Torsion can rotate 0-15, HBA <10, HBD <5, and PSA <140 [9]. Gendarusin A-E compound has 
an LD50 value between 500-2000 which is 566-1213 mg / kg and is included in the toxicity class 
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4. Compounds classified in class IV and V show relatively low toxicity, and the higher LD50 
value that means the lower toxicity [10]. 
Prediction of cytotoxic activity is done by docking Gendarusin AE compounds withreceptors 
Estrogen Alfa (2JF9) which were previously validated by receptors by performing redocking 
molecularto select the most ideal chain. This chain selection can be seen from the RMSD results 
obtained in the redocking process. If the RMSD value obtained <2Å means the value is ideal 
[11]. In table 2 ER α (Chain A) has an RMSD value of 0.81054 which shows that chain A has an 
ideal RMSD compared to others. 
In table 3, the Rerank Score of the Gendarusin compound is the smallest value compared to the 
others, which is -70, 6169. This indicates that the compound Gendarusin A has a high affinity 
and approaches the Rerank Score of tamoxifen as a comparison. The smaller the value of the 
bond energy, the more stable it is. The more stable the ligand and receptor binding, the greater 
the activity [12]. Gendarusin compounds A, C, D, E have hydrogen bonds with the amino acid 
Glu 380. In previous studies tamoxifen had a hydrogen bond with amino acids Glu 380 and Arg 
394 which could increase its antagonistic activity (13). This shows that the compound 
Gendarusin also has the same activity as tamoxifen which inhibits the growth of cancer cells. 
 
CONCLUSION  
Gendarusin AE compounds do not meet the Lipinski law of five and have low toxicity. 
Gendarusin A compound has the lowest Rerank Score compared to others and means the highest 
activity. Gendarusin compounds have almost the same activity as tamoxifen as indicated by the 
presence of hydrogen bonds with the amino acid Glu 380. 
ACKNOWLEDGMENTS  
Thanks to Prof. Dr. Siswandono, Apt., MS, who has given access to theapplication 
Molegro Virtual Docker 6.0. 
 
REFERENCES 
[1] Mansjoer, A. 2002. Ascaris. In : Kapita Selekta Medicine. Volume 1, Issue 3. Jakarta:  
Aesculapius Media FKUI. Pages : 416 – 418. 
[2] Depkes RI. 2013. Indonesia Health Profile 2013 . Jakarta: Ministry Health of Republic 
Indonesia.  
[3] Bruce. A., Chabner., Thomas. G., Roberts. Jr. 2005. Chemotherapy and The War On 
Cancer. Nature Review. Volume 5.  
61 
J. Islamic Pharm. 2019. 4(1): 56-64 
 
J. Islamic Pharm., an open access journal 
ISSN: 2527-6123 
[4] Siswandono., Widiandani, T., Hardjono, S. 2017. Docking and Cytotoxicity Test on 
Human Breast Cancer Cell Line (T47D) of N- (Allycalbamothioyl)-3-chlorobenzamide 
an D-(Allycarmothioyl)-3,-4-dichlorobenzamide. Research Journal of Pharmaceutical, 
Biological and Chemical Sciences. 8(2). 
[5] Widiyanti, P., Prajogo, B., Hikmawanti Erni, N,P. 2016. Cytotoxicity of Justicia 
gendarussa Burm F. Leaf Extracts On Molt-4 Cell. Indonesian Journal of Tropical and 
Infectious Disease. 6(1).  
[6] Achmad. H., Supriatno., Marhamah. Rasmidar. 2014. Anticancer and Antiproliferation 
Activity of Ethnose Ant Nest(Myrmecodya Pendans) On Human Tongue Cancer Cells 
Manusia SP-C1. Dentofasial. 13(1): 1-6.   
[7] Muchtaridi., Yanuar, A., Megantara, S., Purnomo, H., 2018. Basic In Drug Design. First 
Edition. Jakarta: Prenadamedia Group.  
[8] CLCbio. 2013. Moelgro Virtual Docker User Manual, MVD 2013.6.0 for Windows, 
Linux, and Mac OS X.  Molegro A CLC bio company. 
[9] Lipinski, C.R., Lombardo, F., Dominy, B.W. and Feeney, F.J. 1997. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Advanced Drug Delivery Reviews. 23.3-25. 
[10] Supandi, Yeni, Merdekawati, F. 2018. In Silico Study of Pyrazolylaminoquinzolube 
Toxicity by Lazar, Protox, and Admet Predictor. Journal of Applied Pharmaceutical 
Science. 8(9): 119-129.  
[11] Pratama, R.M. 2016. Moleculer Docking Study of Quinolin Derived Compunds Against 
Estrogen-α Receptor. Surya Medika Journal. 2(1).  
[12] Hardjono, S., Siswodihardjo, S., Pramono, P., Darmanto, W. 2016. Quantitative 
Structure- Cytotoxic Activity Relationship 1- (Benzoyloxy)urea an Its Derivative. 
Current Drug Discovery Technologies. 13(2), 101-108.  
[13] Setiawati, A., Ruswanto, F.O.D., Yuliani, S.H., Istyastono, E.P. 2014. Anticancer 
Activity Of Mangosteen Pericarp Dry Extract Against Mcf-7 Breast Cancer Cell Line 
Through Estrogen Receptor -α. Indonesian J.Pharm. 25(119-124).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
J. Islamic Pharm. 2019. 4(1): 56-64 
 
J. Islamic Pharm., an open access journal 
ISSN: 2527-6123 
Table 1. Prediction of Physical and Chemical Properties and Toxicity 
Compound TParameters of Five Lipinski Rules and Toxicity Application 
of Five 
Lipinski 
Rules 
A* B* C* D* E* F* G* H* I* J** K** 
 
Gendarusin A 
534.47 -
1.1152 
3 13 9 213.149 Yes No No 566 4 No 
 
Gendarusin B 
532.498 0.16 3 12 8 214.720 No No No 1213 4 No 
Gendarusin C 
534.47 -
1.1152 
3 13 9 213.149 Yes No No 566 4 No 
Gendarusin D 
534.47 -
1.1152 
3 13 9 213.149 Yes No No 566 4 No 
Gendarusin E 
534.47 -
1.1152 
3 13 9 213.149 Yes No No 566 4 No 
Tamoxifen 
371.524 5.9961 8 2 0 168.649 Yes No No 1190 4 No 
 
Table 2. Result of Receptor Validation of α-Estrogen (2JF9) 
Receptor (2JF9) RMSD Score (Å) 
ER α (Chain A) 0.81054 
ER α (Chain B) 58.3341 
ER α (Chain C) 58.3149 
 
Table 3. Hydrogen Bonding, Steric Bonding and Rerank Score of Compounds 
Compound Hidrogen Bond and Distance (Å) Steric Compund and Distance 
(Å) 
Rerank Score 
Gendarusin A Asp 351 (3,23) Val 355 (3,03) -70,9817 
Glu 380 (3,21 & 2,97) Leu 354 (2,95 & 3,13) 
Trp 383 (2,67) Glu 380 (3,18 & 3,14) 
Trp 383 (3,07) 
Gendarusin B Ala 340 (2,71) Leu 525 (2,91; 2,87; 3,18; 3,15) -68,9485 
Asp 351 (2,52) Thr 347 (3,01 & 2,45) 
Leu 346 (2,72) Leu 346 (3,09) 
Thr 347 (2,52) Ala 350 (2,87) 
Leu 525 (3,06) Met 343 (3,01 & 2,45) 
Gendarusin C Glu 380 (3,37) Leu 525 (3,16) -67,1363 
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Leu 354 (2,86 & 3,18) 
Trp 383 (2,84 & 3,01) 
Gendarusin D Asp 351 (3,22) Val 355 (2,93) -67,6663 
Trp 383 (2,99) Leu 354 (3,18 & 2,77) 
Glu 380 (2,70; 2,90; 3,26; 3,36) Asp 351 (3,02) 
Met 522 (3,19) 
Trp 383 (3,16; 2,80; 3,16) 
Gendarusin E Leu 525 (3,02) Asp 351 (3,07) -69,6190 
Asp 351 (2,60) Trp 383 (3,09; 3,08; 2,85; 3,13) 
Glu 380 (3,30) 
Tamoxifen - Phe 404 (3,18) -101,287 
 
 
 
 
Figure 1. Two dimensional interaction between Gendarusin A-E and Estrogen Chain A (Red: 
Protein; Blue: original ligand; green: Gendarusin A; Yellow: Gendarusin B; Light 
blue: Gendarusin C; Purple: Gendarusin D; Gray: Gendarusin F) 
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Figure 2. The two-dimensional form of hydrogen bonds Gendarusin A (A), gendarusin B (B), 
gendarusin C (C), gendarusin D (D), gendarusin E (E), and tamoxifen (F) in the 
Estrogen Alpha receptor (ERα) with the code 2JF9 PDB. The blue lines show as 
hydrogen bonds, red lines as steric bonds, and green lines as electrostatic interactions. 
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